Pyxis Oncology 주식 가격. PYXS - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

2.26

매수가

2.25

매도가

2.26

거래량

5,457,154

3.80 일간 변동폭 4.31

1.35 52주 범위 6.85

market_cap

134.393M

전일 종가

4.16

개장가

4.25

최근 거래 시간

100

2.26

(formt)

마지막 거래 시간

재정 규모

US$ 21,842,394

VWAP

4.0025

평균 볼륨(3m)

557,504

발행 주식

59,465,729

배당수익률

주가수익률

-3.09

주당순이익(EPS)

-1.24

매출

순이익

-73.79M

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the ... Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

pyxisoncology.com

본부

Wilmington, Delaware, USA

설립됨

Pyxis Oncology Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker PYXS. The last closing price for Pyxis Oncology was US$4.16. Over the last year, Pyxis Oncology shares have traded in a share price range of US$ 1.35 to US$ 6.85.

Pyxis Oncology currently has 59,465,729 shares in issue. The market capitalisation of Pyxis Oncology is US$247.38 million. Pyxis Oncology has a price to earnings ratio (PE ratio) of -3.09.

Form 8-K - Current report

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and...

Form S-8 - Securities to be offered to employees in employee benefit plans

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at...

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-2.49	-52.4210526316	4.75	5.5	1.92	757379	4.21886701	CS
4	-1.23	-35.2435530086	3.49	5.5	1.92	617304	4.13814843	CS
12	-1.4	-38.2513661202	3.66	5.5	1.92	557504	3.78801334	CS
26	-1.85	-45.0121654501	4.11	5.5	1.92	513247	3.62608967	CS
52	0.84	59.1549295775	1.42	6.85	1.35	556140	4.07363843	CS
156	-10.34	-82.0634920635	12.6	13.3	1.1	596779	3.98208724	CS
260	-16.74	-88.1052631579	19	19	1.1	585556	4.16255027	CS

가장 활성
% 상승자
% 패자

기호	가격	볼륨
FBRXForte Biosciences Inc	US$ 13.60 (129.53%)	28.92M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	279.33M
XCURExicure Inc	US$ 11.01 (89.18%)	22.91M
AGFYAgrify Corporation	US$ 37.4635 (68.00%)	921.45k
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	198.66M
SKKSKK Holdings Limited	US$ 4.55 (-47.28%)	815.74k
QMMMQMMM Holdings Limited	US$ 0.713999 (-43.78%)	4.58M
XTKGX3 Holdings Company Ltd	US$ 0.0901 (-37.82%)	5.68M
PRFXPainReform Ltd	US$ 1.02 (-27.14%)	4.95M
GLEGlobal Engine Group Holding Ltd	US$ 3.81 (-26.59%)	228.33k
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.191 (17.39%)	651.25M
DBGIDigital Brands Group Inc	US$ 0.1345 (15.35%)	325.57M
NVDANVIDIA Corporation	US$ 145.89 (-0.76%)	304.46M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	279.33M
ELABElevai Labs Inc	US$ 0.0211 (-0.94%)	198.72M